Purple Biotech Highlights Positive Phase 2 Data for CM24 and Advances Lead Program IM1240 to Phase 1
PPBT sits 30% above its 52-week low of $0.533.
Summary
Purple Biotech released an updated corporate presentation detailing positive Phase 2 results for CM24 in pancreatic cancer, the advancement of its lead IM1240 program to Phase 1, and a cash runway into H1 2027.
Key Events · Product Development and Regulatory · PPBT
-
Positive CM24 Phase 2 Data
CM24 demonstrated a 19% reduction in the risk of death and a 25% reduction in the risk of progression or death in metastatic pancreatic cancer patients, with even stronger results in biomarker-enriched populations.
-
Lead Program IM1240 Progress
The CAPTN-3 platform's lead asset, IM1240, completed GLP toxicology studies and is slated for IND submission in Q3 2026 and Phase 1 initiation in H2 2026.
-
Extended Cash Runway
The company's cash position provides a runway into H1 2027, covering key development milestones for its pipeline.
-
Multiple 2026 Catalysts
Several value-creating milestones are anticipated in 2026, including interim data for NT219 and potential CM24 partnerships.
Analysis · PPBT · Life Sciences
Purple Biotech's updated corporate presentation outlines significant progress across its oncology pipeline and confirms a solid financial runway. The company reported positive Phase 2 efficacy data for CM24 in pancreatic cancer, showing a notable reduction in the risk of death and progression, particularly in biomarker-enriched patient populations. This data positions CM24 for potential partnership. Additionally, its lead CAPTN-3 platform asset, IM1240, is on track for IND submission in Q3 2026 and Phase 1 initiation in H2 2026, representing a key de-risking event for the novel tri-specific antibody platform. The company also confirmed a cash runway into H1 2027, providing funding for these critical milestones and reducing near-term financing concerns for this micro-cap biotech.
At the time of this filing, PPBT was trading at $0.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1M. The 52-week trading range was $0.53 to $3.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.